<DOC>
	<DOCNO>NCT00462553</DOCNO>
	<brief_summary>This phase I trial study side effect best dose sunitinib gemcitabine treat patient pancreatic cancer solid tumor . Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use hemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving sunitinib together gemcitabine may kill tumor cell .</brief_summary>
	<brief_title>Sunitinib Gemcitabine Treating Patients With Pancreatic Cancer Other Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) sunitinib malate gemcitabine hydrochloride patient adenocarcinoma pancreas solid tumor . II . Determine toxicity regimen patient . OUTLINE : This dose-escalation study . Patients receive gemcitabine hydrochloride IV 30 minute day 1 8 OR day 1 , 8 , 15 . Patients also receive oral sunitinib malate daily day 1-21 OR day 1-28 . Treatment repeat every 21 day OR every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gemcitabine hydrochloride sunitinib malate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 10 patient may treat recommend phase II dose ( RPTD ) , generally dose level maximally administer dose . After completion study treatment , patient follow 30 day periodically thereafter .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Criteria : Histologically cytologically confirm pancreatic adenocarcinoma OR solid tumor : Not amenable curative therapy Previously untreated metastatic pancreatic adenocarcinoma allow Measurable evaluable disease No history know brain metastasis , spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease screen CT scan MRI scan ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy &gt; = 12 week Absolute neutrophil count &gt; = 1,500/mm3 Platelet count &gt; = 100,000/mm3 Hemoglobin &gt; = 8.5 g/dL Bilirubin = &lt; 1.5 mg/dL Creatinine normal OR creatinine clearance &gt; = 60 mL/min AST ALT = &lt; 2.5 time upper limit normal ( ULN ) ( = &lt; 5 time ULN due underlie disease ) Calcium = &lt; 12.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 month completion study therapy LVEF normal MUGA scan ECHO baseline Deep venous thrombosis pulmonary embolism allow provide clinically stable adequately treat No preexist thyroid abnormality result inability maintain thyroid function normal range use medication No history allergic reaction attribute compound similar chemical biological composition sunitinib malate No history follow within past 6 month : Myocardial infarction Ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation &gt; = 3 beat row ) Severe/unstable angina Severe peripheral vascular disease ( i.e. , claudication ) Procedure peripheral vasculature Coronary/peripheral artery bypass graft Cerebrovascular accident No history follow within past 6 month : Transient ischemic attack ; Clinically significant bleeding require red blood cell transfusion No NYHA class III IV heart disease : Patients NYHA class II disease stable medication eligible No ongoing cardiac dysrhythmias &gt; = grade 2 , atrial fibrillation grade , significant EKG abnormalities No hypertension control medication systolic blood pressure ( BP ) &lt; 140 mm Hg diastolic BP &lt; 90 mm Hg No condition impair ability swallow retain sunitinib malate tablet , include follow : Gastrointestinal tract disease result inability take oral medication Requirement IV alimentation Prior surgical procedure affect absorption Active peptic ulcer disease No gastrointestinal perforation intraabdominal abscess within past 28 day No serious nonhealing infection bone fracture No severe acute chronic medical condition , psychiatric condition , laboratory abnormality would preclude study therapy May receive number prior systemic therapy More 4 week since prior radiotherapy surgery recover More 4 week since prior therapy recover Prior gemcitabine hydrochloride allow No prior sunitinib malate therapy direct VEGF , include follow : Sorafenib ; Bevacizumab ; Vatalanib ; AZD2171 ; VEGF Trap ; Investigational antiangiogenic therapy More 7 day since prior concurrent CYP3A4 inhibitor , include follow : Ketoconazole Itraconazole Clarithromycin Erythromycin Diltiazem Verapamil Indinavir Ritonavir Nelfinavir Saquinavir Atazanavir Delavirdine More 12 day since prior concurrent CYP3A4 inducer , include follow : Rifampin Rifabutin Carbamazepine Phenobarbital Phenytoin Hypericum perforatum ( St. John 's wort ) Efavirenz Tipranavir No concurrent agent proarrhythmic potential , include follow : Terfenadine Quinidine Procainamide Disopyramide Sotalol Probucol Bepridil Haloperidol Risperidone Indapamide Flecainide No concurrent combination antiretroviral therapy HIVpositive patient No concurrent treatment another clinical trial : Participation nontherapeutic clinical trial allow QTc &lt; 500 msec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>